Bone Marrow Micrometastases Studied by an Immunomagnetic Isolation Procedure in Extremity Localized Non-metastatic Osteosarcoma Patients
Hematogenous spread of tumor cells is an early event in osteosarcoma and present in the majority of patients at primary diagnosis. Eradication of such micrometastases by adjuvant combination chemotherapy is crucial for survival. However, a survival plateau of 60-70% was reached over two decades ago, above which it seems difficult to further advance with the currently available therapies.
In this study we have, by an immunomagnetic isolation procedure, examined the presence and prognostic impact of disseminated tumor cells in bone marrow aspirates taken at primary diagnosis in a cohort of 41 non-metastatic patients with extremity localized, high-grade osteosarcoma.
KeywordsHuman Serum Albumin Disseminate Tumor Cell Primary Bone Sarcoma Suspected Bone Adjuvant Combination Chemotherapy
- 1.Malawer MM, Helman LJ, O’Sullivan B. Sarcomas of bone. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer – Principles & Practice of Oncolog. 7th ed. Philadelphia: Lippincott-Raven Publishers; 2005:1638-1686.Google Scholar
- 3.Huvos AG. Osteogenic sarcoma. In: Huvos AG, ed. one Tumors. Diagnosis, treatment and prognosis. Philadelphia: WB Saunders; 1991:85-155.Google Scholar
- 17.Carlson MJ. Circulating sarcoma cells: the incidence of 3thymidine labeling in the peripheral blood of normal and sarcoma patients. Thesis – University of Minnesota 1978.Google Scholar
- 18.Kaiser TE. The detection of tritiated thymidine labeled cells in the peripheral blood of sarcoma patients and the nature of these cells bearing prognostic significance for sarcoma patients. Thesis – University of Minnesota 1985.Google Scholar
- 36.Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003;5442/9:5442-5453.Google Scholar